Identification of HER2 mutations in lung cancer and methods of treatment
Methods are provided for treating lung cancer, and more particularly for treating pulmonary adenocarcinoma in a canine subject. The method may comprise assaying a biological sample from the canine subject, such as a tumor sample or a plasma sample, for a mutation in the HER2 gene. The mutation may include HER2 V659E, HER2 A664T, or HER2 K676E. If one or more of the mutations is present in the biological sample, the methods further include treating the canine subject by administering a therapeutically effective amount of an inhibitor of HER2. For example, a HER2 V659E may indicate increase sensitivity to a HER2 inhibitor. The HER2 inhibitor may include a small molecule HER2 inhibitor, such as trastuzumab, neratinib, lapatinib, erlotinib, and pertuzumab.
1. A method of treating lung cancer in a canine subject, comprising the steps of:
receiving a biological sample from the subject;
analyzing the biological sample for one or more missense mutations in HER2, wherein the one or more missense mutations in HER2 comprises V659E, A664T and/or K676E;
and treating the subject with an inhibitor of HER2 if the one or more missense mutations is present.
2. The method of claim 1 , wherein the HER2 inhibitor is selected from the group comprising trastuzumab, neratinib, lapatinib, erlotinib, and pertuzumab.
3. The method of claim 1 , wherein the lung cancer is canine pulmonary adenocarcinoma.
4. The method of claim 1 , wherein the biological sample is a tumor sample or a plasma sample.
5. The method of claim 4 , wherein cell-free tumor DNA (ctDNA) from plasma is analyzed.
6. The method of claim 1 , wherein the analyzing step comprises subjecting the biological sample to amplicon and/or exome sequencing.
7. A method of treating lung cancer in a canine subject, comprising the steps of:
receiving a biological sample from the subject;
adding to a mixture comprising the biological sample a first primer consisting of SEQ ID NO: 1 and a second primer consisting of SEQ ID NO: 2;
subjecting the mixture to conditions that allow nucleic acid amplification;
detecting in the amplified nucleic acid the presence of a HER2 V659E missense mutation; and
treating the subject with an inhibitor of HER2 if the HER2 V659E missense mutation is present.
8. The method of claim 7 , wherein the detecting step comprises sequencing a product of the nucleic acid amplification.
9. The method of claim 7 , wherein the HER2 inhibitor is selected from the group comprising trastuzumab, neratinib, lapatinib, erlotinib, and pertuzumab.
10. The method of claim 7 , further comprising adding to the mixture a probe consisting of SEQ ID NO: 3.
11. The method of claim 10 , wherein the lung cancer is canine pulmonary adenocarcinoma.
12. The method of claim 7 , wherein the biological sample is a tumor sample or a plasma sample.
13. The method of claim 12 , wherein cell-free tumor DNA (ctDNA) from plasma is analyzed.
14. A method of treating lung cancer in a canine subject, comprising the steps of:
receiving a biological sample from the subject;
analyzing the biological sample for one or more missense mutations selected from the group consisting of HER2 V659E, HER2 A664T, and HER2 K676E, and one or more missense mutations selected from the group consisting of KRAS G12D/V, SMAD4 D351Y/G, and TP53 R239Q/G;
and administering, if one or more of the HER2 mutations is present, a therapeutically effective amount of a pharmaceutical composition selected from the group consisting of trastuzumab, neratinib, lapatinib, erlotinib, and pertuzumab.
15. The method of claim 14 , wherein the analyzing step comprises subjecting the biological sample to amplicon and/or exome sequencing.
16. The method of claim 14 , wherein the lung cancer is canine pulmonary adenocarcinoma.
17. The method of claim 14 , wherein the biological sample is a tumor sample or a plasma sample.
18. The method of claim 17 , wherein cell-free tumor DNA (ctDNA) from plasma is analyzed.